Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 21

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 2
Chunk 21
---
 $397,507 for the same period ended 2024. The difference
is primarily attributable to the recognition by the Company of a Derivative Loss of $376,312 recognized in the period ended in 2025.

Working
capital deficit increased by $598,321 from September 30, 2024 to June 30, 2025, primarily due to increase in Derivative Liability.

                                                        Nine                                             
                                                        Months ended 30-Jun                              
                                                                                     2025          2024  
  Net                                                   $                        (241,500      (544,247  
  cash used in operating activities                                                                      
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────
  Net                                                                             242,545       458,058  
  Net                                                   $                           1,045       (59,189  

Liquidity
and Capital Resources

Operating
Activities

Net
cash used in operating activities for the nine months ended June 30, 2025 was $241,500, compared to $544,247, for the same period ended
2024. The decrease in cash used in operating activities is primarily attributable to decreased operating expenses incurred by the Company
during the nine months ended June 30, 2025 as compared to the same period ended 2024.

Financing
Activities

Net
cash generated by financing activities for the nine months ended June 30, 2025 was $242,545 which consisted of proceeds from notes payables.

  24  

Liquidity
& Capital Resources Outlook

As
of June 30, 2025, the Company had cash of $ 1,761 and net working deficit of approximately $5.8 million.

The
Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and it has
incurred and expects to continue incur significant research & development cost for products development.

The
accompanying financial statements have been prepared as if the Company will continue as a going concern. The Company has incurred significant
operating losses and negative cash flows from operations since inception. As of June 30, 2025, the Company had cash of approximately
$1,761 and an accumulated deficit of approximately $21 million. The Company has incurred recurring losses, experienced recurring negative
operating cash flows, and requires significant cash resources to execute its business plans. The Company is dependent on obtaining additional
working capital funding from the sale of equity and/or debt securities in order to continue to